Forma Therapeutics Announces Closing of Public Offering & Exercise in Full of the Underwriters’ Option to Purchase Addition...
December 15 2020 - 3:35PM
Business Wire
Forma Therapeutics Holdings, Inc. (Nasdaq: FMTX), a
clinical-stage biopharmaceutical company focused on rare
hematologic diseases and cancers, today announced the closing of an
underwritten public offering of 6,095,000 shares of its common
stock, including the exercise in full by the underwriters of their
option to purchase up to an additional 795,000 shares of common
stock, at a public offering price of $45.25 per share. The
aggregate gross proceeds from the offering, before deducting
underwriting discounts and commissions and offering expenses, were
approximately $275.8 million. All of the shares in the offering
were offered by Forma.
Jefferies, SVB Leerink and Credit Suisse acted as joint
book-running managers for the offering. Oppenheimer & Co acted
as lead manager for the offering.
This press release shall not constitute an offer to sell or a
solicitation of an offer to buy, nor shall there be any offer or
sale of these securities in any state or other jurisdiction in
which such offer, solicitation or sale would be unlawful prior to
the registration or qualification under the securities laws of any
such state or other jurisdiction.
Registration statements relating to these securities became
effective on December 10, 2020. The offering was made only by means
of a prospectus, copies of which may be obtained from: Jefferies
LLC, Attention: Equity Syndicate Prospectus Department, 520 Madison
Avenue, 2nd Floor, New York, NY 10022, by telephone at (877)
821-7388, or by email at prospectus_department@Jefferies.com; SVB
Leerink LLC, Attention: Syndicate Department, One Federal Street,
37th Floor, Boston, MA 02110, by telephone at (800) 808-7525, ext.
6132, or by email at syndicate@svbleerink.com; Credit Suisse
Securities (USA) LLC, Attention: Prospectus Department, 6933 Louis
Stephens Drive, Morrisville, NC 27560, by telephone at (800)
221-1037, or by email at usa.prospectus@credit-suisse.com; or
Oppenheimer & Co. Inc., Attention: Syndicate Prospectus
Department, 85 Broad Street, 26th Floor, New York, NY, 10004, by
telephone at (212) 667-8055, or by email at
EquityProspectus@opco.com.
About Forma Therapeutics
Forma Therapeutics is a clinical-stage biopharmaceutical company
focused on the development and commercialization of novel
therapeutics to transform the lives of patients with rare
hematologic diseases and cancers.
View source
version on businesswire.com: https://www.businesswire.com/news/home/20201215006042/en/
Media Contact: Kari Watson, +1 781-235-3060 MacDougall
kwatson@macbiocom.com
Investor Contact: Mario Corso Forma Therapeutics
mcorso@formatherapeutics.com
Forma Therapeutics (NASDAQ:FMTX)
Historical Stock Chart
From Jul 2024 to Aug 2024
Forma Therapeutics (NASDAQ:FMTX)
Historical Stock Chart
From Aug 2023 to Aug 2024